Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease

• Timothy M. Butler,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Katherine Johnson-Camacho,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Myron Peto,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Nicholas J. Wang,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Tara A. Macey,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• James E. Korkola,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Theresa M. Koppie,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Christopher L. Corless,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Joe W. Gray,

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯
• Paul T. Spellman

  * E-mail: spellmap@ohsu.edu

  Affiliation Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon, United States of America

  ⨯